SG11201908422YA - Glycopolymers sequestering carbohydrate-binding proteins - Google Patents

Glycopolymers sequestering carbohydrate-binding proteins

Info

Publication number
SG11201908422YA
SG11201908422YA SG11201908422YA SG11201908422YA SG 11201908422Y A SG11201908422Y A SG 11201908422YA SG 11201908422Y A SG11201908422Y A SG 11201908422YA SG 11201908422Y A SG11201908422Y A SG 11201908422YA
Authority
SG
Singapore
Prior art keywords
international
basel
carbohydrate
pct
binding proteins
Prior art date
Application number
Inventor
Hélène Blanche Pfister
Ruben Herrendorff
Beat Ernst
Original Assignee
Polyneuron Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyneuron Pharmaceuticals Ag filed Critical Polyneuron Pharmaceuticals Ag
Publication of SG11201908422YA publication Critical patent/SG11201908422YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT Hu omit VIII °nolo omioomi 011111mo ow (10) International Publication Number WO 2018/167230 Al (51) International Patent Classification: A61K 47/64 (2017.01) C07H 15/203 (2006.01) CO7H 15/04 (2006.01) A61P 31/04 (2006.01) CO7H 15/12 (2006.01) A61P 37/00 (2006.01) (21) International Application Number: PCT/EP2018/056583 (22) International Filing Date: 15 March 2018 (15.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17161162.7 15 March 2017 (15.03.2017) EP (71) Applicant: POLYNEURON PHARMACEUTICALS AG [CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH). (72) Inventors: PFISTER, Helene Blanche; Missionsstr. 8, 4055 Basel (CH). HERRENDORFF, Ruben; St. Jo- hanns-Vorstadt 47, 4056 Basel (CH). ERNST, Beat; Hohenweg 1, 4312 Magden (CH). (74) Agent: SPERRLE, Martin; Latscha Schollhorn Partner AG Austrasse 24, 4051 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) 1-1 • (54) Title: GLYCOPOLYMERS SEQUESTERING CARBOHYDRATE-BINDING PROTEINS 0 (57) : The invention relates to polymers comprising carbohydrate ligands and moieties, respectively, that bind to carbohy- drate-binding proteins (CBPs), as well as to these carbohydrate ligands, and to their use in diagnosis and therapy of diseases that are N associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In particular, the invention relates to polymers comprising a multitude of said carbohydrate ligands and moieties, respectively, mimicking carbohydrates that are bound by 1-1 ▪ CBPs which belong to the group of (i) bacterial exotoxins, (ii) agglutinins, and (iii) immune complex deposit-forming immunoglobu- lins. Furthermore, the invention relates to the use of these polymers and carbohydrate ligands and moieties respectively, in diagnosis as O 1-1 well as for the treatment of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit N formation. In one embodiment, the polymer is polylysine.
SG11201908422Y 2017-03-15 2018-03-15 Glycopolymers sequestering carbohydrate-binding proteins SG11201908422YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161162 2017-03-15
PCT/EP2018/056583 WO2018167230A1 (en) 2017-03-15 2018-03-15 Glycopolymers sequestering carbohydrate-binding proteins

Publications (1)

Publication Number Publication Date
SG11201908422YA true SG11201908422YA (en) 2019-10-30

Family

ID=58489474

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908422Y SG11201908422YA (en) 2017-03-15 2018-03-15 Glycopolymers sequestering carbohydrate-binding proteins
SG10202110067R SG10202110067RA (en) 2017-03-15 2018-03-15 Glycopolymers sequestering carbohydrate-binding proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202110067R SG10202110067RA (en) 2017-03-15 2018-03-15 Glycopolymers sequestering carbohydrate-binding proteins

Country Status (13)

Country Link
US (1) US20200079808A1 (en)
EP (1) EP3595730A1 (en)
JP (1) JP2020514414A (en)
KR (1) KR20200011411A (en)
CN (1) CN110545851A (en)
AU (1) AU2018235063A1 (en)
BR (1) BR112019019145A2 (en)
CA (1) CA3056206A1 (en)
EA (1) EA201991959A1 (en)
IL (1) IL269251A (en)
MX (1) MX2019010857A (en)
SG (2) SG11201908422YA (en)
WO (1) WO2018167230A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022224035A2 (en) 2021-04-20 2022-10-27 Polyneuron Pharmaceuticals Ag Anti-gm1 antibody binding compounds
EP4245764A1 (en) 2022-03-18 2023-09-20 RemAb Therapeutics SL New carbohydrate derivatives as mimetics of blood group a and b antigens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132156A0 (en) * 1997-04-18 2001-03-19 Novartis Ag Neoglycoproteins
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
EP3915999A1 (en) * 2014-03-13 2021-12-01 Universität Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
WO2017046172A1 (en) * 2015-09-16 2017-03-23 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids

Also Published As

Publication number Publication date
SG10202110067RA (en) 2021-10-28
AU2018235063A1 (en) 2019-10-03
CN110545851A (en) 2019-12-06
JP2020514414A (en) 2020-05-21
BR112019019145A2 (en) 2020-04-14
CA3056206A1 (en) 2018-09-20
US20200079808A1 (en) 2020-03-12
IL269251A (en) 2019-11-28
WO2018167230A1 (en) 2018-09-20
MX2019010857A (en) 2020-01-27
EP3595730A1 (en) 2020-01-22
EA201991959A1 (en) 2020-03-17
KR20200011411A (en) 2020-02-03

Similar Documents

Publication Publication Date Title
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201900699QA (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201906509WA (en) Lipocalin muteins with binding affinity for lag-3
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201810801QA (en) Brain delivery protein
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201808686VA (en) Synthesis of indazoles
SG11201900361RA (en) Methods of treating prostate cancer
SG11201906728TA (en) Multimeric oligonucleotides having decreased kidney clearance
SG11202000141WA (en) Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof
SG11201810403VA (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201809882XA (en) Pharmaceutical combinations for treating cancer